The phase I/II IMMU-132-01 study has demonstrated preliminary efficacy of SG in previously treated HR + /HER2- metastatic BC patients, showing encouraging overall response rate (ORR), median progression-free survival (mPFS), and median OS [9]. The gene discussed is ERBB2; the disease is breast cancer.